Excision BioTherapeutics Presents Data from HBV and HSV Programs at the ASGCT 2025 Annual Meeting

Excision BioTherapeutics, Inc. (“Excision” or the “Company”), a biotechnology company developing CRISPR-based therapies to cure viral infectious diseases, today announced new data presentations from its preclinical programs, hepatitis B virus (HBV), EBT-107 and herpes simplex virus (HSV-1) keratitis, EBT-104 at the 2025 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place May 13–17 in New Orleans, Louisiana.

CytoTronics Expands Pixel Capability with Multi-modal Cardiac Application for Early Screening of Drug Candidates in Cardiovascular Research

CytoTronics, Inc., a pioneer of semiconductor-based platforms for discovery in cell biology, launched their novel Cardiac application today—the next key offering in its Pixel application portfolio. The first-of-its-kind, multi-modal application lets drug discovery scientists focused on cardiovascular disease and cardiotoxicology measure the electrical activity, contractility and structure of cardiomyocytes in a single assay at scale in 96-and 384-well plates.